Key Highlights
- Net loss for the third quarter narrowed to USD 49.4 million, or USD 0.74 per common share, from USD 50.6 million, or USD 0.77, in the same quarter of 2025.
- Operating expenses fell to USD 52.6 million from USD 55.6 million, with Research and Development at USD 40.2 million and general and administrative expense at USD 12.4 million.
- Cash, cash equivalents and short-term investments were USD 289.6 million on September 30, 2026, plus USD 24.2 million of Long-Term Investments and interest receivable.
- A New Drug Application for zipalertinib was initiated in October 2026 under the FDA's Real-Time Oncology Review program, with completion of the submission expected in November.
Quarterly Loss Edges Lower as Interest Income Slips
Cullinan Therapeutics (NASDAQ:CGEM) filed its Quarterly Report on November 10, 2026 for the three months ended September 30, 2026. The company develops T cell engagers, drugs that direct immune cells to attack disease-causing cells, for autoimmune diseases and cancer. It has no approved products and no product revenue. Net loss was USD 49,388 thousand versus USD 50,610 thousand, and the nine-month net loss fell to USD 152.8 million, or USD 2.31 per common share, from USD 169.2 million. Interest income dropped to USD 3.3 million from USD 5.1 million on lower Investment income. Operating spend fell mainly because a USD 20.0 million upfront license fee for velinotamig was paid in 2025, which flatters the nine-month comparison.
Zipalertinib NDA and a Crowded Pipeline Set the Agenda
The filing says the global Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion lung cancer met its primary endpoint at interim analysis, with a statistically significant improvement in progression-free survival. Zipalertinib is co-developed with an affiliate of Taiho Pharmaceutical. Cullinan is eligible for USD 30.0 million from Taiho on US approval in previously treated patients and up to USD 100.0 million on first-line approval, and both sides share US pre-tax profits equally. Elsewhere, a potentially registrational Phase 2 trial of CLN-049 in acute myeloid leukemia began in October, and CLN-978 single target dose data in lupus, rheumatoid arthritis and Sjögren's disease are planned for December 2026.
Cash Funds a Year of Work, With Dilution and Trial Risks Intact
Operating activities used USD 127.3 million of cash in the nine months, versus USD 137.6 million a year earlier, and the accumulated Deficit reached USD 740.9 million. Management expects cash, investments and interest receivable to fund operations for at least 12 months from the filing date, though it cautions the plan could prove wrong. The company has an at-the-market program allowing up to USD 200.0 million of stock sales, and made no sales through September 30, 2026. The filing notes that further Equity raises would dilute holders. Clinical-stage spending on CLN-978 rose to USD 9.8 million for the quarter from USD 5.3 million, while the discontinued CLN-619 and CLN-617 programs now carry little cost.
Where Things Stand
Possibly, based on the filing, but approval is a separate question. Cullinan Therapeutics (NASDAQ:CGEM) said an NDA for zipalertinib was initiated in October under a real-time review program and is expected to be completed in November, while USD 289.6 million in cash supports operations for at least 12 months. An FDA decision date is not given in the material. The company still posts losses near USD 50 million a quarter, so the next markers are NDA completion, the December CLN-978 data and ASH presentation, and any use of the at-the-market program.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...